Yifan Pharmaceutical Co., Ltd. (SHE: 002019)
China
· Delayed Price · Currency is CNY 12.71
-0.22 (-1.70%)
Nov 13, 2024, 3:04 PM CST
Yifan Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -331.54 | -551.07 | 191.22 | 278.4 | 968.39 | 903.47 | Upgrade
|
| Depreciation & Amortization | 265.13 | 265.13 | 228.43 | 207.18 | 177.01 | 153.69 | Upgrade
|
| Other Amortization | 14.69 | 14.69 | 9.48 | 6.88 | 9.43 | 7.81 | Upgrade
|
| Loss (Gain) From Sale of Assets | -2.57 | -2.57 | 0.56 | -14.83 | 0.04 | 0.85 | Upgrade
|
| Asset Writedown & Restructuring Costs | 872.46 | 872.46 | 102.13 | 38.25 | 6.6 | 72.13 | Upgrade
|
| Loss (Gain) From Sale of Investments | 15.06 | 15.06 | 17.63 | 4.49 | -6.95 | -39.49 | Upgrade
|
| Provision & Write-off of Bad Debts | 60.47 | 60.47 | 29.12 | 21.34 | 8.19 | 12.24 | Upgrade
|
| Other Operating Activities | -361.47 | -237.89 | 38.44 | 56.52 | 40.34 | 53.61 | Upgrade
|
| Change in Accounts Receivable | -10.25 | -10.25 | -103.77 | -18.59 | -117.71 | -58.05 | Upgrade
|
| Change in Inventory | -109.39 | -109.39 | -167.1 | -80.48 | 21.86 | -113.48 | Upgrade
|
| Change in Accounts Payable | 62.88 | 62.88 | 156.63 | -99.34 | -49.22 | -59.11 | Upgrade
|
| Change in Other Net Operating Assets | 21.79 | 21.79 | 23.15 | -10.3 | 82.7 | 48.08 | Upgrade
|
| Operating Cash Flow | 444.54 | 348.58 | 472.07 | 301.23 | 1,109 | 937.24 | Upgrade
|
| Operating Cash Flow Growth | -2.58% | -26.16% | 56.71% | -72.83% | 18.27% | -19.96% | Upgrade
|
| Capital Expenditures | -518.95 | -504.09 | -542.27 | -571.74 | -715.71 | -866.07 | Upgrade
|
| Sale of Property, Plant & Equipment | 2.12 | 5.02 | 7.84 | 17.7 | 0.96 | 0.82 | Upgrade
|
| Cash Acquisitions | - | - | - | -42 | -39.81 | -818.81 | Upgrade
|
| Divestitures | 6.35 | 1.06 | 1.2 | 15.9 | 3 | - | Upgrade
|
| Investment in Securities | -365.13 | -39.13 | -137.58 | 66.6 | -26 | 86.5 | Upgrade
|
| Other Investing Activities | -31.38 | 4.3 | 0.65 | 5.64 | 7.01 | 11.11 | Upgrade
|
| Investing Cash Flow | -906.99 | -532.84 | -670.17 | -507.89 | -770.55 | -1,586 | Upgrade
|
| Long-Term Debt Issued | - | 1,855 | 1,789 | 2,928 | 1,957 | 2,544 | Upgrade
|
| Long-Term Debt Repaid | - | -2,044 | -1,897 | -2,448 | -2,210 | -2,069 | Upgrade
|
| Net Debt Issued (Repaid) | 559 | -189.38 | -107.72 | 480.27 | -252.97 | 474.94 | Upgrade
|
| Issuance of Common Stock | - | - | 0.85 | 1 | - | 199.33 | Upgrade
|
| Repurchase of Common Stock | -38 | -38 | -53.56 | -121.47 | -1.62 | - | Upgrade
|
| Common Dividends Paid | -196.92 | -72.47 | -86.38 | -138.39 | -201.98 | -192.34 | Upgrade
|
| Other Financing Activities | 355.74 | 330.62 | 234.15 | 0.75 | -111.38 | -330.84 | Upgrade
|
| Financing Cash Flow | 679.81 | 30.78 | -12.66 | 222.16 | -567.95 | 151.09 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.59 | 14.59 | 59.56 | -20.85 | 1.33 | 9.58 | Upgrade
|
| Net Cash Flow | 216.78 | -138.88 | -151.2 | -5.36 | -228.66 | -488.55 | Upgrade
|
| Free Cash Flow | -74.41 | -155.5 | -70.21 | -270.51 | 392.8 | 71.17 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | 451.93% | -83.89% | Upgrade
|
| Free Cash Flow Margin | -1.49% | -3.82% | -1.83% | -6.14% | 7.27% | 1.37% | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.13 | -0.06 | -0.22 | 0.32 | 0.06 | Upgrade
|
| Cash Income Tax Paid | 343.8 | 362.22 | 91.5 | 220.66 | 456.31 | 451.41 | Upgrade
|
| Levered Free Cash Flow | -201.54 | -168.05 | -347 | -430.33 | -173.92 | 3.97 | Upgrade
|
| Unlevered Free Cash Flow | -190.19 | -120.83 | -293.35 | -383.71 | -129.5 | 47.98 | Upgrade
|
| Change in Net Working Capital | 45.64 | -90.36 | 96.08 | 183.23 | 316.77 | -39.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.